Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
Shares of medical device company Boston Scientific (NYSE:BSX)
fell 4.6% in the afternoon session after the company agreed to acquire Penumbra in a transaction valued at approximately $14.5 billion, marking its largest deal in two decades.
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has been defined by the explosive rise of GLP-1 weight-loss drugs and the volatility of post-pandemic earnings, Abbott has successfully completed a pivot that many [...]
Date: January 9, 2026 Introduction As the global healthcare landscape undergoes a seismic shift toward personalized medicine and AI-integrated care, Medtronic plc (NYSE: MDT) stands at a critical juncture. Once viewed as a reliable but sluggish dividend aristocrat, the world’s largest standalone medical technology firm has spent the last 24 months aggressively shedding its "legacy" [...]
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence infrastructure captured the lion's share of investor attention, the healthcare sector has emerged as the unexpected powerhouse
As 2025 draws to a close, the financial markets are entering the new year with a sense of cautious exuberance. Despite a year of navigating fluctuating interest rates and geopolitical tensions, the consensus among Wall Street’s elite is clear: 2026 is poised to be a year of significant corporate
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best and worst performers in the medical devices & supplies - diversified industry.
New York, NY – November 20, 2025 – UBS Group has adjusted its outlook on Medtronic plc (NYSE: MDT) stock, raising its price target to $102.00 from $95.00. This upward revision follows Medtronic's stronger-than-expected second-quarter fiscal 2026 earnings report, which showcased robust performance driven by key segments and innovative technology.
Boston Scientific has been treading water for the past six months, recording a small loss of 3.5% while holding steady at $102.88. The stock also fell short of the S&P 500’s 13% gain during that period.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
